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Summary  
A nomogram consisting of hypertension, neutrophil-lymphocyte-ratio and NT-proBNP is an 
effective tool for predicting in-hospital survival probability of patients with COVID-19. This 

























Background: The outbreak of coronavirus disease (COVID-19) in 2019 has spread 
worldwide and continues to cause great threat to peoples’ health as well as put pressure on 
the accessibility of medical systems. Early prediction of survival of hospitalized patients will 
help the clinical management of COVID-19, but such a prediction model which is reliable 
and valid is still lacking. 
Methods: We retrospectively enrolled 628 confirmed cases of COVID-19 using positive RT-
PCR tests for SARS-CoV-2 in Tongji Hospital in Wuhan, China. These patients were 
randomly grouped into a training cohort (60%) and a validation cohort (40%). In the training 
cohort, least absolute shrinkage and selection operator (LASSO) regression analysis and 
multivariate Cox regression analysis were utilized to identify prognostic factors for in-
hospital survival of patients with COVID-19. A nomogram based on the three variables was 
built for clinical use. Areas under the ROC curves (AUC), concordance index (C-index) and 
calibration curve were used to evaluate the efficiency of the nomogram in both the training 
and validation cohorts. 
Results: Hypertension, higher neutrophil-to-lymphocyte ratio and increased NT-proBNP 
value were found to be significantly associated with poorer prognosis in hospitalized patients 
with COVID-19. The three predictors were further used to build a prediction nomogram. The 
C-index of the nomogram in the training and validation cohorts was 0.901 and 0.892, 
respectively. The AUC in the training cohort was 0.922 for 14- day and 0.919 for 21-day 
probability of in-hospital survival, while in the validation cohort was 0.922 and 0.881, 
respectively. Moreover, the calibration curve for 14- day and 21-day survival also showed 
high coherence between the predicted and actual probability of survival. 
Conclusion: We managed to build a predictive model and constructed a nomogram for 
predicting in-hospital survival of patients with COVID-19. This model represents good 
performance and might be utilized clinically in the management of COVID-19. 
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In December, 2019, an unknown pneumonia emerged in Wuhan, China, which turned out to 
be the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) viruses [1]. Since its emergence, COVID-19 has spread across 
China and globally, with high morbidity and mortality [2]. With the progression of this 
pandemic, public health is greatly threatened and healthcare systems worldwide are under 
great pressure. Progress in vaccine development has brought hope of potentially preventing 
the disease [3]. However, effective drugs are still lacking for clinical treatment. Prediction of 
patients’ outcomes as early as admission will help to identify those at high risk of poor 
outcome, and active supportive treatments may be given to these patients to improve their 
prognosis. Considering this, a predictive model with reliable efficacy is of great importance 
for the clinical management of COVID-19. 
Recently, a number of models or factors have been proposed to predict the severity or 
survival of patients confirmed with COVID-19. For example, one study reported that severe 
cases of COVID-19 tend to have a higher neutrophil-lymphocyte-ratio (NLR) [4], while 
another study suggested that monitoring platelet-to-lymphocyte ratio (PLR) has beneficial 
effects on the management of patients with COVID-19 [5]. Increased N terminal pro B type 
natriuretic peptide (NT-proBNP) has also been found to be correlated with greater disease 
severity of COVID-19 [6]. However, most of these studies only studied the predictive value 
of indicators for disease severity and their prognostic value for outcomes of COVID-19 have 
been less explored. In addition, sample sizes in these studies are usually relatively small. The 
predictive value of these factors or models remains to be validated and their clinical 
practicability to be tested. 
Nomograms are graphical mathematical models that have been used to predict prognosis by 
estimating clinical events and integrating significant prognostic factors in numerous diseases 
[7-9]. In this study, by enrolling an adequate number of patients from the first epicenter, 


















evaluating the incidence of severe COVID-19 infection, and to compare existing clinical 




Patients of this retrospective study were enrolled during the period between January and 
March 2020, from Tongji Hospital. All the patients recruited were confirmed with COVID-19 
by positive RT-PCR tests for SARS-COV-2 from throat-swab specimens and had a definite 
outcome of either hospital discharge or death. Those who were still receiving treatment at the 
time of data collection were not included due to unknown outcome. This study was approved 
by the Ethics Committee of Tongji Hospital. The ethics committee of the hospital waived the 
written informed consent from patients with COVID-19. Diagnosis of COVID-19 was made 
according to the interim guidance of the World Health Organization [10]. 
 
Data Collection 
Laboratory confirmation of SARS-CoV-2 infection was conducted in Tongji Hospital. 
Methods for laboratory confirmation of SARS-CoV-2 infection have been described 
previously [11]. Throat-swab specimens were obtained from all patients after admission for 
SARS-CoV-2 detection. Those who tested positive by real-time RT-PCR were considered 
confirmed cases. Baseline population characteristics (age and gender), clinical data (signs and 
symptoms on admission, comorbidities and laboratory findings upon admission), treatment 
and outcomes data were collected in detail from electronic medical records of these patients. 
Laboratory tests included blood assays (e.g. leukocytes, lymphocytes, neutrophils), 
inflammatory indicators (procalcitonin, C-reactive protein, erythrocyte sedimentation rate, 
interleukin-6), coagulation profile, liver and renal function and cardiac enzymes. In order to 
minimize sampling bias, data were obtained by communicating effectively with medical 
workers and double checking with them. After enrollment, all patients were randomly 


















were constructed in the training cohort based on symptoms, comorbidities and results of the 
first laboratory tests after admission, and then validated in the validation cohort. 
 
Statistical Analysis 
Continuous variables were expressed as median and interquartile range (IQR), while 
categorical variables were presented as frequencies and percentages (%). To compare the 
difference between groups, we used chi-squared test for categorical variables and Wilcoxon 
rank-sum tests for continuous variables. NLR and PLR were calculated based on results of 
patients' first blood assay results after admission. Survival time was defined as time from 
hospital admission to date of death or discharge. In the training cohort, potential prognostic 
factors were screened out using LASSO regression, and factors selected in LASSO regression 
[12-15] were further analyzed in multivariate Cox proportional hazard model to identify 
significantly the prognostic factors associated with survival of COVID-19. Subsequently, 
factors with prognostic significance in the multivariate Cox regression analysis were utilized 
to build an in-hospital survival-prediction model and a nomogram was used to visualize the 
model. A receiver operating characteristic curve (ROC), under the ROC curve (AUC) and 
Harrell’s concordance index (C-index) were used to assess discrimination of the model, while 
the calibration plot was used to graphically evaluate the calibration of the nomogram in both 
training and validation cohorts. The value of the C-index ranges from 0.5 to 1.0, with 0.5 
indicating random chance and 1.0 demonstrating perfect discrimination. The performance of 
the model was also augmented with 10-fold cross validation in the validation cohort. All 
analyses were conducted using R software (version 3.6.3), and P values less than 0.05 were 





















Symptoms and Comorbidities of enrolled patients with COVID-19 
Table 1 shows the details of baseline characteristics of those patients enrolled. Of the total 
patients in this study, the median age was 61years (IQR: 53-70 years) and 300 patients 
(47.8%) were male. Most patients in the overall cohort had fever (83.0%) and cough (66.9%), 
while 216 (34.4%) patients had shortness of breath. Headache (24.9%), sore throat (22.5%) 
and diarrhea (22.3%) were less common. Hypertension (167 [26.6%]) was the most common 
coexisting disease followed by diabetes (14.2%), while coronary heart disease, chronic 
kidney disease, chronic obstructive pulmonary disease and cancer were present in 14.2%, 
6.4%, 2.5%, 1.9%, and 1.6% of total patients, respectively. We randomly allocated 390 
patients (60%) to the training cohort and 238 (40%) to the validation cohort. There was no 
significant difference in most characteristics between the two cohorts (all P value > 0.05) 
(Table 1). 
Laboratory findings after admission 
In the overall cohort, abnormal laboratory findings included decreased lymphocyte count 
(49.8%), increased neutrophil (22.9%) and leukocyte (23.6%) count as well as prolonged 
activated partial thromboplastin time (24.6%) and prothrombin time (28.9%). 67.5% of 
patients had increased D-Deimer. Elevated level of inflammatory biomarkers such as lactose 
dehydrogenase, C-reactive protein and Interleukin were present in over half of the patients 
(Table 1). Similar findings were also observed in the training and validation cohorts. 
Treatment and outcome 
Antiviral therapy (70.2%) was the most common therapy for hospitalized patients with 
COVID-19 followed by oxygen therapy (68.7%). Antiviral drugs included lopinavir-
ritonavir, oseltamivir and remdesivir. Oxygen therapy was mainly oxygen inhalation (65.1%) 
and mechanical ventilation (3.6%). Antibiotics, glucocorticoids and intravenous 
immunoglobulin were administered to 63.1%, 27.1% and 23.6% of patients, respectively. 



















Prognostic factors of in-hospital survival of patients with COVID-19. 
Data regarding age, gender, symptoms (including fever, cough, shortness of breath, headache, 
sore throat, diarrhea nausea and vomiting), chronic medical illnesses (including kidney 
disease, cancer, hypertension, diabetes, chronic obstructive pulmonary disease and coronary 
heart disease) and laboratory findings (including NLR, PLR, hemoglobin, activated partial 
thromboplastin time, prothrombin time, D-Dimer, albumin, alanine aminotransferase, 
aspartate aminotransferase, blood urea nitrogen, creatinine, lactose dehydrogenase, C‐
reactive protein, N-terminal pro-B-type natriuretic peptide, procalcitonin and interleukin-6) 
were considered potential prognostic factors affecting in-hospital survival and were included 
in LASSO regression. The results showed that age, cancer, hypertension, coronary heart 
disease, NLR, NT-proBNP, albumin, C-reactive protein and creatinine obtained from the 
training cohort were associated with in-hospital survival when the optimal lambda was 0.028 
(Figure S1). These factors were subsequently included in the multivariate Cox regression 
analyses (Table 2), and the results revealed that hypertension, NLR and NT-proBNP were 
independent prognostic factors affecting in-hospital survival of COVID-19. Patients with 
hypertension, higher NLR and increased NT-proBNP tended to have poorer prognosis, while 
the prognosis of patients without hypertension, lower NLR and NT-proBNP value was 
relatively better. 
 
Nomogram construction and validation 
The three independent prognostic factors (hypertension, NLR and NT-proBNP) were 
incorporated to establish a predictive model for predicting of 14- and 21-day probability of 
in-hospital survival (Figure1). A final Cox regression analysis including only the three 
predictors was conducted to demonstrate the fitted coefficients and hazard ratio of each 
predictor in the model (Table 3). This model was visualized using a nomogram, the usage of 
which is illustrated with an assumptive patient with hypertension, NLR of 4.0 and NT-
proBNP of 1000 pg/mL upon admission (vertical red lines). Points for hypertension, NLR 
and NT-proBNP were 0, 22 and 36, respectively. The total point added up to 58 for this 


















hospital survival. Performance of this nomogram was assessed by C-index, AUC and 
calibration plots. The C-index of the predictive model was 0.901 in the training cohort and 
0.892 in the validation cohort. Subsequently, we drew the ROC curves for 14- day and 21- 
day survival in both the training and validation cohorts with the AUC value indicated (Figure 
2). In the training cohort, AUC for predicting 14- and 21- day survival was 0.922 and 0.919, 
and was 0.922 and 0.881 in the validation cohort, indicating high discrimination of the model 
(Table 4). The calibration plots also showed excellent agreement between the predicted 
probability of survival and actual observation, which indicates good calibration of the model 
(Figure 3). To further evaluate the generalizability of model performance, we conducted 10-
fold cross-validation for the model in the training cohort. The mean (standard deviation) of 
the C-index was 0.899 (0.0004) in cross-validations, and the AUC value was 0.920 (0.001) 
and 0.921 (0.001) for 14-day and 21-day survival prediction, respectively, which indicates 
stable and favorable performance of the model. 
 
Comparison of the NLR, PLR, NT-proBNP and our model. 
Previous studies have reported the predictive value of NLR, PLR, NT-proBNP for COVID-
19 severity, but their association with outcomes of COVID-19 has rarely been reported. We 
also compared the performance of our model incorporating hypertension, NLR and NT-
proBNP to that of single PLR, NLR and NT-proBNP in predicting survival. The results 
showed that the prognostic value of PLR for survival was limited (Table 4). NLR exhibited 
higher C-index and AUC for 14- and 21- day survival compared with PLR or NT-proBNP. 
However, it did not perform better than our new model in both the training and validation 
cohorts according to the AUC and C-index (Table 4), suggesting that the new model is 





















COVID-19 is an acute infectious disease caused by a new coronavirus (SARS-CoV-2), which 
has spread quickly and brought a huge burden on human health and health care systems [16]. 
A previous study reported that 26% of patients received intensive care, and the in-hospital 
mortality was 4.3% [17]. Half a year has passed since it first emerged, and the number of 
patients is still increasing rapidly globally, with no specific treatment method currently 
available.  
There is a growing body of evidence suggesting that several clinical indicators can be used to 
predict the severity and outcomes of patients with COVID-19. In our study, we used LASSO 
regression and multivariate Cox regression analysis to identify significant factors associated 
with in-hospital survival of COVID-19. Consequently, hypertension, NLR and NT-proBNP 
were identified and used to develop the prognostic nomogram in our study. This nomogram 
demonstrated good discrimination and calibration in predicting the 14- day and 21- day 
probability of survival of patients with COVID-19, as assessed by the C-index, AUC value 
and calibration plots, indicating good performance and high value for clinical use. 
In this study, hypertension (26.6%) is associated with poor prognosis of COVID-19. Previous 
clinical studies have shown that COVID-19 patients with pre-existing hypertension are more 
likely to incur disproportionately worse outcome [17-19]. Our study also suggested that 
patients with hypertension are more likely to suffer poorer prognosis compared to those 
without. Besides, patients with hypertension are older, and old age is known to be a risk 
factor for unfavorable outcome of adult in-patients with COVID-19 [19]. These patients 
might also have other unfavorable conditions that render them at a higher risk of poor 
prognosis, and great importance should, therefore, be attached to such patients in order to 
improve their health and survival outcomes. 
We also found that increased NLR and NT-proBNP levels were significantly associated with 
poor outcome of COVID-19 patients. Increased NLR indicates elevated neutrophil count or 
decreased lymphocyte count, or both. Decreased lymphocyte count, or lymphopenia, has 
been reported to be predictive of poor outcome [20]. Lymphocytes are crucial in the defense 


















compromised immune function in infected patients, leading to poor conditions and outcomes. 
NT-proBNP is a biomarker for heart failure that is released from cardiomyocytes in response 
to ventricular wall stretch caused by high intra-ventricular pressure [21]. In COVID-19 cases, 
enlarged pulmonary artery  diameter, which indicates pulmonary hypertension, was found to 
be associated with death from COVID-19 [22]. In the condition of pulmonary hypertension, 
right ventricular pressure is also increased, correspondingly triggering release of NT-proBNP, 
which in combination with the pulmonary artery diameter can serve as a prognostic factor of 
survival of COVID-19. Significantly increased NT-proBNP levels are indicative of 
compromised heart function or heart failure, which renders patients with COVID-19 more 
prone to unfavorable prognosis [23]. 
Previously published studies have reported that NLR or NT-proBNP can be a predictor of 
severe COVID-19 cases. For example, a study based on 61 patients demonstrated that NLR 
could be an early predictor of severe disease [24], with higher AUC, sensitivity and 
specificity compared to MuLBSTA and CURB-6 models that have been widely used to 
evaluate mortality due to pneumonia [25-27]. Another study with 245 patients illustrated that 
NLR is an independent prognostic factor of survival in COVID-19 patients, especially for 
male patients [28]. NT-proBNP has been used to assess prognosis in a variety of diseases, 
such as heart failure and acute respiratory distress syndrome (ARDS) [29, 30]. Recently, one 
study with a sample of 54 patients indicated that higher NT-proBNP value is associated with 
poor outcomes of severe patients with COVID-19, suggesting that NT-proBNP is a 
prognostic factor in patients with severe COVID-19 [31].  
However, the sample sizes of these studies are relatively small and their findings have not 
been validated possibly due to lack of adequate patients, which might decrease the clinical 
practicability of their findings. In addition, studies which predict in-hospital survival of 
COVID-19 are still limited. In this study, we confirmed that NLR and NT-proBNP were 
significant prognostic factors associated with outcomes of patients with COVID-19 and were 
used to construct a predictive nomogram for clinical use.  
As this pandemic progresses to global proportion, the situation in many cities worldwide 
resembles or is even worse than that in Wuhan at the early stages of the COVID-19 crisis, 


















shortage of medical supplies. Hospitals and medical workers in these healthcare settings are 
facing similar challenges to those experienced in Wuhan. Given this situation, our prediction 
model based on patients from one of the major hospitals at the center of the first epidemic is 
of great value for clinical reference and use. It might help clinicians to identify early patients 
at greater risk of death and give intensive and active treatment to reduce mortality. 
The study had some limitations. First, this is a retrospective, single center study and may 
have some inevitable biases. The outcomes of in-hospital patients with different conditions 
(such as medical force, supplies and number of infections) might differ. Patients in this study 
were enrolled during the peak of COVID-19 explosion when there was shortage of medical 
resources and inadequate experience of treating such a disease. In some areas with low 
epidemic and medical burden, patients with comparable conditions may have better outcomes 
than those treated in overburdened centers. In such case, combining survival prediction with 
the nomogram with actual clinical situations is recommended. Second, NT-proBNP is not a 
routine laboratory test and might not be available in some community hospitals, which 
potentially reduces the practicability of the nomogram in areas with limited medical 
resources. Despite these limitations, we managed to build a predictive model of in-hospital 
survival of patients with COVID-19 with high accuracy. We hope that this prediction model 




A prognostic model and nomogram for predicting in-hospital survival of COVID-19 was 
built and demonstrated good discrimination and calibration. It allowed prediction of 
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Table 1 Demographic and clinical features, treatment and outcomes of patients in the training 
and validation cohorts. 
 
Table 2 Multivariate cox analysis of potential prognostic factors identified by LASSO 
regression in the training cohort. 
  
Table 3 Coefficients, hazard ratio and 95% confidence interval of the three predictors in the 
final model. 
 
Table 4 C-index and AUC of 7-day and 14- day overall survival in each of the PLR, NLR, 




















Figure 1 The final nomogram consisting of NLR, hypertension and NT-proBNP is displayed. 
The usage of the nomogram is illustrated in an assumptive patient with hypertension, NLR of 
4.0 and NT-proBNP of 1000 pg/mL upon admission (vertical red lines). According to the 
nomogram, points for hypertension, NLR and NT-proBNP were 0, 22 and 36, respectively. 
The total point added up to 58 for this patient, which represented approximately 0.75 and 
0.62 of 14-day and 21-day in-hospital survival probability (indicated in the nomogram). 
 
Figure 2 ROC curve and AUC of the nomogram in the training and validation cohort. A and 
B indicate the ROC curve and AUC of the nomogram in predicting 14-day and 21-day 
survival in the training cohort, while C and D illustrate 14-day and 21-day survival prediction 
in the validation cohort.  
 
Figure 3 The calibration plot of the nomogram in the training and validation cohort. The 
calibration plot for predicting 14-day (A) and 21-day (B) survival in the training cohort and 
for predicting 14-day (C) and 21 day (D) survival in the validation cohort. Actual rate of 
survival is shown on the y-axis, and the nomogram- predicted probability of survival is 


























All patients  










Age, (median (IQR 
a
)) 63 (53, 70) 63 (53, 70) 63 (53, 71) 0.515 
Male 300 (47.8 %) 182 (46.7 %) 118 (49.6 %) 0.531 
Symptoms  
Fever  521 (83.0 %) 327 (83.8 %) 194 (81.5 %) 0.519 
Cough  420 (66.9 %) 265 (67.9 %) 155 (65.1 %) 0.521 
Breath shortness  216 (34.4 %) 132 (33.8 %) 84 (35.3 %) 0.776 
Headache  71 (24.9 %) 41 (25.2 %) 30 (24.6 %) 1.000 
Sore throat  64 (22.5 %) 39 (23.9 %) 25 (20.5 %) 0.586 
Diarrhea  140 (22.3 %) 81 (20.8 %) 59 (24.8 %) 0.282 
Nausea and vomiting  70 (24.6 %) 37 (22.7 %) 33 (27.0 %) 0.481 
Comorbidities     
Chronic kidney disease 7 (2.5 %) 5 (3.1 %) 2 (1.6 %) 0.701 
Cancer 
b
  10 (1.6 %) 4 (1.0 %) 6 (2.5 %) 0.261 
Hypertension  167 (26.6 %) 111 (28.5 %) 56 (23.5 %) 0.206 
Diabetes  89 (14.2 %) 54 (13.8 %) 35 (14.7 %) 0.856 
COPD 
c
  12 (1.9 %) 8 (2.1 %) 4 (1.7 %) 0.977 
Coronary heart disease  40 (6.4 %) 15 (3.8 %) 25 (10.5 %) 0.002 




















193 (49.5 %) 120 (50.4 %) 
0.157 
Platete< 125*10^9/L  54 (8.6 %) 33 (8.5 %) 21 (8.8 %) 0.728 
Hemoglobin< 130 g/L 368 (58.6 %) 226 (57.9 %) 142 (59.7 %) 0.850 
Activated partial thromboplastin 
time > 42 s  
144 (24.6 %) 91 (25.1 %) 53 (23.8 %) 
0.907 
Prothrombin time > 14.5 s  181 (28.9 %) 117 (30.0 %) 64 (27.0 %) 0.477 
D-Deimer≥0.5 μg/mL  405 (67.5 %) 253 (68.0 %) 152 (66.7 %) 0.802 
Albumin< 30 g/dL 312 
(49.8 %) 
192 (49.4 %) 120 (50.6 %) 
0.412 
Alanine aminotransferase> 41 U/L  124 
(19.7 %) 
81 (20.8 %) 43 (18.1 %) 
0.470 




85 (21.8 %) 55 (23.1 %) 
0.776 
Blood urea nitrogen< 3.6 mmol/L 92 (14.6 %) 54 (13.8 %) 38 (16.0 %) 0.540 
Creatinine> 84 (F) and > 104 (M) 
μmol/L  
69 (11.0 %) 38 (9.7 %) 31 (13.0 %) 
0.257 
Lactose dehydrogenase> 225 U/L 402 (64.9 %) 251 (65.4 %) 151 (64.3 %) 0.768 
C‐reactive protein> 10 mg/L  352 (56.5 %) 217 (55.8 %) 135 (57.7 %) 0.185 
N-terminal pro-B-type natriuretic 
peptide (median (IQR)), pg/mL  



















Procalcitonin> 0.05 ng/mL 169 (34.1 %) 95 (31.2 %) 74 (38.5 %) 0.247 
Interleukin 6 ≥ 7 pg/mL  251 
(54.6 %) 
151 (53.7 %) 100 (55.9 %) 
0.725 
Treatment and outcome  
Oxygen inhalation 401 
(65.1 %) 
253 (66.1 %) 148 (63.5 %) 
0.460 
Ventilation  22 (3.6 %) 11 (2.9 %) 11 (4.7 %) 0.658 
Antibacterial therapy 396 (63.1 %) 253 (64.9 %) 143 (60.1 %) 0.262 
Antivirus therapy  441 (70.2 %) 288 (73.8 %) 153 (64.3 %) 0.014 
Glucocorticoids 170 (27.1 %) 110 (28.2 %) 60 (25.2 %) 0.467 
Intravenous immunoglobulin 
therapy  
148 (23.6 %) 91 (23.3 %) 57 (23.9 %) 
0.937 
Hospital stay (median (IQR)), days  19 (12, 27) 19 (11, 27) 19 (12, 27) 0.589 









69 (17.7 %) 52 (21.8 %) 
a. Interquartile range 
b. Any type of cancer 
c. Chronic Obstructive Pulmonary Disease 




































Table 2 Multivariate cox analysis of potential prognostic factors identified by LASSO 
regression in the training cohort.  
 
Factors Coefficients HR 
c
 [95% CI 
d
] p value  
Age     
Age < 60  Reference  
  Age≥60 0.393 1.481 [0.739, 2.969] 0.268 
Hypertension    
  No  Reference  
  Yes 0.619 1.857 [1.034, 3.337] 0.038 
Cancer    
No  Reference  
Yes 0.921 2.512 [0.525, 12.025] 0.248 
Coronary Heart Disease    
No  Reference  
Yes 0.694 2.002 [0.876, 4.575] 0.100 
NLR 
a
    
< 2.9  Reference  
3 ~ 5.9 2.439 11.470 [1.461, 90.069] 0.020  
6 ~ 9.9 3.192 24.343 [2.888, 205.209] 0.003  
> 10 3.603 36.722 [4.795, 281.216] 0.001  
NT-proBNP
b 
,pg/mL    
< 200  Reference  
200 ~ 400 1.327 3.771 [1.365, 10.420] 0.010  
401 ~ 800 1.478 4.387 [1.672, 11.512] 0.003  
801 ~ 1600 1.901 6.690 [2.703, 16.557] < 0.001 
1601 ~ 2000 1.418 4.130 [1.346, 12.673] 0.013  
> 2000 1.987 7.290 [2.656, 20.012] < 0.001  
Albumin    
≥ 35g/L  Reference  
< 35g/L 0.197 1.217 [0.548, 2.702] 0.629 
C‐reactive protein    
≤ 10 mg/L  Reference  
>10 mg/L -0.012 0.987 [0.102, 9.549] 0.991 
Creatinine    
≤ 104 g/L  Reference  
> 104 g/L 0.645 1.907 [0.950, 3.825] 0.069 
 
a, neutrophil-to-lymphocyte ratio;  
b, N terminal pro B type natriuretic peptide  
c, hazard ratio;  


























 Coefficients HR (95% CI) p-value 
Hypertension    
No Reference   
Yes 0.742 2.100 (1.290, 3.419) 0.003 
NLR    
< 2.9 Reference   
3 ~ 5.9 2.372 10.722 (1.377, 83.490) 0.023 
6 ~ 9.9 2.912 18.386 (2.240, 150.928) 0.007 
> 10 3.729 41.622 (5.472, 316.624) <0.001 
NT-proBNP, pg/mL    
< 200 Reference   
200 ~ 400 1.282 3.605 (1.365, 9.522) 0.01 
401 ~ 800 1.526 4.601 (1.796, 11.785) 0.001 
801 ~ 1600 2.018 7.524 (3.105, 18.231) <0.001 
1601 ~ 2000 1.969 7.164 (2.523, 20.343) <0.001 

































Table 4 C-index and AUC of 7-day and 14- day overall survival in each of the PLR, NLR, 





models Training cohort Validation cohort 
 c-index AUC c-index AUC 
  14- day 21- day  14- day 21- day 
PLR 0.667 0.674 0.702 0.649 0.625 0.658 
NT-proBNP 0.84 0.855 0.858 0.811 0.877 0.803 
NLR 0.845 0.879 0.889 0.815 0.849 0.819 
Hypertension +NLR 
+ NT- proBNP 
0.901 0.922 0.919 0.892 0.922 0.881 
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; NT- proBNP, N terminal pro B 
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